Clinical Report: Assessment of a Long Human Respiratory Syncytial Virus Strain

Overview

This study evaluates a recombinant RSV strain lacking the M2-2 gene, demonstrating reduced viral replication and enhanced immune responses in BALB/c mice. The findings support the potential of this strain as a candidate for live-attenuated vaccines against RSV.

Background

Incorporate statistics on RSV morbidity and mortality to emphasize the public health need.

Data Highlights

Key Findings

• The recombinant strain RLΔM2-2 showed reduced replication in HEp-2 and Vero cells compared to the parental strain.
• In BALB/c mice, RLΔM2-2 resulted in lower lung viral loads and less body weight loss than RLΔM2-2112.
• Intranasal immunization with RLΔM2-2 induced robust systemic and pulmonary immune responses.
• The immune response included preF-specific antibodies and RSV-specific CD8+ T-cell responses with a Th1-biased profile.
• Vaccination with RLΔM2-2 conferred protection against subsequent RSV challenges without enhanced respiratory disease.

Clinical Implications

The findings suggest that the M2-2 deletion strategy may enhance the safety and efficacy of RSV live-attenuated vaccines. This approach could lead to the development of effective immunization options for infants and young children, addressing a critical gap in current RSV prevention strategies.

Conclusion

The study supports the potential of the M2-2 deletion strategy in developing safe and effective RSV vaccines. Further evaluation of this recombinant strain is warranted to advance RSV vaccine development.

Related Resources & Content

1. The Journal of Infectious Diseases, 2025 -- Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices
2. The Journal of Infectious Diseases, 2025 -- Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products
3. PMC, 2020 -- Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children
4. The Journal of Infectious Diseases — Intranasal M2SR (M2-Deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults
5. The Journal of Infectious Diseases — Analysis of Mouse-Adapted Marburg and Ravn Viruses in BALB/c and CD-1 Mouse Models
6. The Journal of Infectious Diseases — Detection of Live Attenuated Measles Virus in the Respiratory Tract Following Subcutaneous Measles-Mumps-Rubella Vaccination
7. The Journal of Infectious Diseases — Development of a Cynomolgus Macaque Model for Investigating Respiratory Illness Induced by Human Adenovirus Type 55
8. Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025 | MMWR
9. Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025 | MMWR
10. Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children - PMC